Amylyx Pharmaceuticals, Inc. (AMLX) SEC filings

AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30

$29.86−1.94 (-6.10%)

Close on Nov 12, 2026Market cap $3.33BP/E –Yield –

SEC filings

40 of Amylyx Pharmaceuticals's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Sep 1, 2026	Sep 8, 2026	SEC EDGAR
Current report	8-K	Aug 19, 2026	Aug 20, 2026	SEC EDGAR
Current report	8-K	Aug 18, 2026	Aug 18, 2026	SEC EDGAR
Current report	8-K	Aug 18, 2026	Aug 18, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jun 4, 2026	Jun 4, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 4, 2026	Apr 23, 2026	SEC EDGAR
Current report	8-K	Mar 24, 2026	Mar 24, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 3, 2026	SEC EDGAR
Current report	8-K	Mar 3, 2026	Mar 3, 2026	SEC EDGAR
Current report	8-K	Jan 8, 2026	Jan 8, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Sep 9, 2025	Sep 10, 2025	SEC EDGAR
Current report	8-K	Aug 27, 2025	Aug 27, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jun 5, 2025	Jun 5, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 8, 2025	SEC EDGAR
Current report	8-K	May 8, 2025	May 8, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 5, 2025	Apr 24, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 4, 2025	SEC EDGAR
Current report	8-K	Mar 4, 2025	Mar 4, 2025	SEC EDGAR
Current report	8-K	Jan 10, 2025	Jan 10, 2025	SEC EDGAR
Current report	8-K	Dec 30, 2024	Dec 30, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 7, 2024	SEC EDGAR
Current report	8-K	Nov 7, 2024	Nov 7, 2024	SEC EDGAR
Current report	8-K	Oct 17, 2024	Oct 17, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Aug 8, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Jul 9, 2024	Jul 10, 2024	SEC EDGAR
Current report	8-K	Jun 21, 2024	Jun 21, 2024	SEC EDGAR
Current report	8-K	Jun 6, 2024	Jun 6, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 9, 2024	SEC EDGAR
Current report	8-K	May 9, 2024	May 9, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Amylyx Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AMLX.

Compare: AMLX vs WVE · AMLX vs BCYC · AMLX vs PRTA · AMLX vs VTVT · AMLX vs SEPN

Revenue growth-100.0% · median 342.1%

Company	Revenue	Growth
SEPN	$96.27M	+336.7%
BCYC	$83.53M	+194.7%
WVE	$70.92M	–
PRTA	$52.74M	+347.4%
VTVT	$36.84M	+216600.0%
AMLX	$0	-100.0%

Company

Next earnings (est.): Mar 2, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 136
Held by institutions: 100.0%
Auditor: Deloitte & Touche LLP
SEC CIK: 1658551

Advertisement
300 × 250

See a number that looks wrong?